BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-140@catalystbrief.girapphe.com
DTSTAMP:20261118T001552Z
LAST-MODIFIED:20261118T001552Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Novartis Pharmaceuticals — Remibrutinib Dose A [May 2027
 ]
DESCRIPTION:Phase 3 primary completion: A Phase 3 Study to Assess Efficacy 
 Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients W
 ith Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1).\nSource: htt
 ps://clinicaltrials.gov/study/NCT06799000\nhttps://catalystbrief.girapphe.
 com/e/140?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/140?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
